Register
Community
Physicians
Editors
Experts
Code of conduct
Blog
Terms of Use
Privacy Policy
Sitemap
Company
About
Publications
Press
Careers
Programs
Journal Club
Targeted Topic
Clinical Trial
Tumor Board
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
•
Non-small cell lung cancer
•
ALK+
Would you consider using ensartinib in patients with ALK positive NSCLC who have progressed on alectinib and lorlatinib?
Related Questions
Would you extrapolate IMPower010 data to offer adjuvant atezolizumab to a patient with N2 PDL1-high (>50%) NSCLC who had been treated with induction chemotherapy followed by definitive R0 resection after partial response?
How do you manage a patient with metastatic NSCLC whose initial mutation testing was limited or results are no longer available?
For patients with KRAS G12C mutated NSCLC, how would you decide between using targeted therapy with sotorasib vs adagrasib?
What is your preferred first line treatment approach for a patient with PDL-1 high (>50%) NSCLC presenting with CNS mets?
Would you hold osimertinib in a patient with a STEMI, and for how long?
Should 1 year of atezolizumab be the standard of care for stage II-IIIA resected PDL1+ NSCLC?
What is your recommended adjuvant approach to resected NSCLC with both PD-L1>1% and EGFR mutation?
Should IMPower010 results be extrapolated to superior sulcus tumors treated with chemoradiation and surgery?
What are best practices for engaging with multidisciplinary colleagues to ensure patients with earlier stage NSCLC are being appropriately considered for novel adjuvant therapies?
Do you recommend surveillance brain MRI in patients with Stage III-IV EGFR-mutated non-small cell adenocarcinoma if they had no evidence of brain metastasis at initial presentation?
